发布时间：2008.10

价格：

Single User PDF Format:$2000
Multi-User License:$3000
Hard Copy:$2200
CD-ROM:$2200

摘要

“Global Vaccine Market Forecast to 2012”, our new research report, states that vaccines, which were earlier thought as a low margin, low growth industry, have emerged as one of the most lucrative segments in the pharmaceutical industry. With a projected CAGR growth of over 16% in the next five years, the industry will emerge as the fastest growing therapy area. The US and Europe represents the two largest vaccine markets (in fact, these tow countries were the largest markets in 2007) and will continue to experience healthy growth in future.

Segment-wise, pediatric vaccines presently dominate the global vaccine market but adult vaccine segments will define the future direction of growth. The cancer vaccine marker, led by cervical cancer vaccines, is presently one of the most lucrative areas for vaccine manufacturers. Overall, cancer vaccines are expected to account for nearly 27% of the total vaccine revenues by 2012.

Owing to lower margins and the mature nature of these markets, the basic and enhanced pediatric markets are expected to show stagnant growth in future. On the other hand, launch of a number of new vaccines will make the addiction, cancer and proprietary pediatrics/adolescent vaccine market highly dynamic. On a whole, the global vaccine market is expected to register revenues in excess of US$ 30 Billion by 2012.

Analysis of the competitive landscape of the market shows its highly concentrated structure, with the top four players accounting for over 86% of the total market in 2007.

Our report gives an extensive and objective analysis on the global market for vaccines. It investigates both the past and current trends in the vaccine market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of vaccines, both in the market and in developing stage. Based on various present and future indicators, the report evaluates the prospects of various vaccine segments. The report can thus give valuable information for manufacturers/investors preparing to enter in these vaccine segments.

Our report provides forecast on

§ Global vaccine revenues
§ Basic pediatrics revenues
§ Enhanced pediatrics revenues
§ Proprietary pediatrics/adolescent revenues
§ Adult/travel revenues
§ Influenza revenues
§ Cancer vaccines revenues
§ Major pediatric and adult vaccines
§ Major geographical markets - US, Europe, China, India, Japan and Brazil
§ US pediatric and adult vaccine markets
§ Revenues of key players
§ Revenues of key vaccine brands

Profiling on Key Players

This section gives a category-wise overview on the key players, including Sanofi-Aventis, GlaxoSmithKline and Novartis, operating in the global vaccine market. It provides vital information, like business overview, current performance, future prospects of key vaccine brands and major merger and acquisitions by the key players to give a rational overview on the competitive landscape of the market.

目录及图表

1. Analyst View
2. The Global Vaccine Market
     2.1 Introduction
     2.2 Market Opportunity Assessment
3. Critical Success & Risk Factors
     3.1 Critical Success Factors
            3.1.1 Disease Prevention
            3.1.2 Higher Margins
            3.1.3 Support from Government & NGOs
            3.1.4 Blockbuster Potential of New Vaccines
            3.1.5 Increasing Population in Developing Countries
            3.1.6 Disease Awareness
     3.2 Critical Risk Factors
            3.2.1 Huge R&D Cost
            3.2.2 Lack of Infrastructure for Trials & Manufacturing
            3.2.3 Effective Vaccine Design
            3.2.4 Vaccine Supply
4. Major Vaccine Segments
     4.1 Basic Pediatrics
     4.2 Enhanced Pediatrics
     4.3 Proprietary Pediatrics
     4.4 Adult/Travel Vaccines
     4.5 Cancer Vaccines
     4.6 Addiction Vaccines
     4.7 Influenza Vaccines
5. Major Pediatric Vaccines
     5.1 Pneumococcal Vaccines
     5.2 Polio Vaccines
     5.3 Varicella Vaccines
     5.4 Meningitis Vaccines
     5.5 Rotavirus Vaccines
     5.6 DTP Vaccines
     5.7 Measles, Mumps & Rubella (MMR) Vaccines
     5.8 Tuberculosis Vaccines
6. Major Adult/Travel & Therapeutic Vaccines
     6.1 Hepatitis B Vaccines
     6.2 Malaria Vaccines
     6.3 Japanese Encephalitis Vaccines
     6.4 Ebola Vaccines
     6.5 Cervical Cancer Vaccines
     6.6 Typhoid Vaccines
     6.7 West Nile Vaccines
     6.8 HIV Vaccines
7. Key Geographical Markets
     7.1 US
     7.2 Europe
     7.3 China
     7.4 India
     7.5 Japan
     7.6 Brazil
8. Competitive Landscape to 2012
     8.1 Revenues & Growth of Key Players
     8.2 Revenues & Growth of Key Vaccine Brands
     8.3 Key Mergers & Acquisitions
     8.4 Major Categories of Players
            8.4.1 Vaccine Majors
            8.4.2 Vaccine-focused Biotech Companies
            8.4.3 Domestic-focused Vaccine Companies
     8.5 Key Company Profiles
            8.5.1 Sanofi-Aventis
            8.5.2 GlaxoSmithKline Plc.
            8.5.3 Merck & Co., Inc.
            8.5.4 Novartis
            8.5.5 Wyeth

List of Figures:

Figure 2-1: Vaccines Horizon* (1960 to 2010)
Figure 2-2: Global - Vaccine Market (in Million US$), 2005-2007
Figure 2-3: Global - Forecast for Vaccine Market (in Million US$), 2008-2012
Figure 3-1: Global - Profit Margin of Vaccines, Generics & Branded Drugs (%), 2007E
Figure 3-2: Global - Vaccine Market by Source of Funding (%), 2001
Figure 3-3: Global - Prevnar Sales (in Million US$), 2003-2007
Figure 3-4: Global - Dose Consumption & Revenue by Regional Income (%), 2005
Figure 4-1: Global - Vaccine Market by Segment (%), 2005-2007
Figure 4-2: Global - Forecast for CAGR of Vaccine Market by Segment (%), 2007 to 2012
Figure 4-3: Global - Forecast for Vaccine Market by Segment (%), 2008-2012
Figure 4-4: Global - Basic Pediatric Vaccine Market (in Million US$) 2005-2007
Figure 4-5: Global - Forecast for Basic Pediatric Vaccine Market (in Million US$), 2008-2012
Figure 4-6: Global - Enhanced Pediatric Vaccine Market (in Million US$) 2005-2007
Figure 4-7: Global - Forecast for Enhanced Pediatric Vaccine Market (in Million US$), 2008-2012
Figure 4-8: Global - Proprietary Pediatrics/Adolescent Vaccine Market (in Million US$), 2005-2007
Figure 4-9: Global - Forecast for Proprietary Pediatrics/Adolescent Vaccine Market (in Million US$), 2008-2012
Figure 4-10: Global - Adult/Travel Vaccine Market (in Million US$), 2005-2007
Figure 4-11: Global - Forecast for Adult/Travel Vaccine Market (in Million US$), 2008-2012
Figure 4-12: Global - Cancer Vaccine Market (in Million US$) 2006 & 2007E
Figure 4-13: Global - Cancer Vaccine by Type in Various Phases of Clinical Development (in Number), Aug 2005
Figure 4-14: Global - Forecast for Cancer Vaccine Market (in Million US$), 2008-2012
Figure 4-15: Global - Forecast for Addiction Vaccine Market (in Million US$), 2008-2012
Figure 4-16: Global - Influenza Vaccine Market (in Million US$), 2005-2007
Figure 4-17: Global - Influenza Vaccine Production by Manufacturer (%), 2006
Figure 4-18: Global - Forecast for Influenza Vaccine Market (in Million US$), 2008-2012
Figure 5-1: Global - Pipeline for Pneumococcal Vaccines
Figure 5-2: Global - Pneumococcal Vaccine Market (in Million US$), 2007 & 2012F
Figure 5-3: Global - Number of Polio Incidences (2004-2007)
Figure 5-4: Global - Countries with Maximum Number of Polio Incidences (2006)
Figure 5-5: Global - Polio Vaccine Market (in Million US$), 2004 & 2011F
Figure 5-6: Global - Inactivated Polio Vaccine Doses (in Million), 2006* & 2011F
Figure 5-7: Global - Meningitis Vaccine Market (in Billion US$), 2004 & 2010F
Figure 5-8: Global - Forecast for Rotavirus Vaccine Market (in Billion US$), 2010
Figure 5-9: Global - Forecast for Rotavirus Vaccine Market by Region (%), 2010
Figure 5-10: Global - Number of Diphtheria Incidences by Region (2007)
Figure 5-11: Global - Number of Pertussis Incidences by Region (2007)
Figure 5-12: Global - Number of nTetanus Incidences by Region (2007)
Figure 5-13: Global - Number of tTetanus Incidences by Region (2007)
Figure 5-14: Global - DTP Combos Market by Player (%), 2004
Figure 5-15: Global - Number of Measles Incidences by Region (2007)
Figure 5-16: Global - Number of Mumps Incidences by Region (2007)
Figure 5-17: Global - Number of Rubella Incidences by Region (2007)
Figure 5-18: Global - Number of Tuberculosis Incidences by Region  (in ‘000), 2006
Figure 6-1: Global - Hepatitis B Surface Antigen Prevalence (%), 2006
Figure 6-2: Global - Hepatitis B Vaccine Market (in Million US$), 1999, 2005, 2006 & 2011F
Figure 7-1: Global - Vaccine Market by Region (%), 2007E
Figure 7-2: Global - Forecast for Vaccine Market by Region (%), 2012
Figure 7-3: Global - Sales Split of Major Vaccine Players by Region (%), 2004
Figure 7-4: US - Vaccine Market (in Billion US$), 2003, 2007E, 2008F & 2013F
Figure 7-5: US - Pediatric Vaccine Market (in Billion US$), 2003, 2007E, 2008F & 2013F
Figure 7-6: US - Hepatitis Vaccine Market (in Million US$), 2003, 2007E, 2008F & 2013F
Figure 7-7: US - Biodefense Vaccine Market (in Million US$), 2003, 2007E, 2008F & 2013F
Figure 7-8: US - Influenza Vaccine Market (in Million US$), 2003, 2007E, 2008F & 2013F
Figure 7-9: US - Travel Vaccine Market (in Million US$), 2003, 2007E, 2008F & 2013F
Figure 7-10: US - Forecast for Developmental Vaccine Market (in Million US$), 2008 & 2013
Figure 7-11: Europe - Vaccine Market (in Million US$), 1996, 2005, 2007E & 2012F
Figure 7-12: China - Vaccine Market (in Million US$), 2006 & 2007E
Figure 7-13: China - Forecast for Vaccine Market (in Million US$), 2008-2012
Figure 7-14: India - Vaccine Market (in Billion INR) 2005–06 to 2007-08E
Figure 7-15: India - Share of Major Players in Vaccine Market (%), 2006-07
Figure 7-16: India - Share of Public & Private Sectors in Vaccine Market (%), Nov 2006
Figure 7-17: India - Share of Domestic Consumption & Exports in Vaccine Market (%), 2005-06
Figure 7-18: India - Forecast for Vaccine Market (in Billion INR), 2008-09 to 2012-13
Figure 7-19: Japan - Vaccine Market (in Million US$) 1996, 2005 & 2007E
Figure 7-20: Japan - Influenza Vaccine Production (in Million Doses), 2004-05 to 2006-07E
Figure 7-21: Japan - Forecast for Vaccine Market (in Million US$), 2008-2012
Figure 7-22: Brazil - Vaccine Market (in Million BRL), 2000, 2004, 2007E, 2008F & 2012F
Figure 7-23: Brazil - Share of Public & Private Sectors in Vaccine Market (%), 2004
Figure 8-1: Global - Share of Major Players in Vaccine Market (%), 2007
Figure 8-2: Global - Forecast for Share of Major Players in Vaccine Market (%), 2012
Figure 8-3: Global - Forecast for CAGR of Major Players in Vaccine Market (%), 2007 to 2012

List of Tables:

Table 2-1: Global - Revenues* & Growth of Major Therapy Areas (in Million US$), 2007 & 2012F
Table 3-1: Global - Number of Deaths due to Diphtheria Averted by Vaccines (in ‘000), 2001
Table 4-1: Global - List of Launched & Under-development Cancer Vaccines by Indiaction
Table 6-1: Global - Number of HIV/AIDS Patients (2007)
Table 7-1: China - Vaccine Classification
Table 7-2: China - Pediatric Vaccine Doses Requirement (in Million)
Table 7-3: Brazil - Vaccine Market by Public & Private Sectors (in Million BRL), 2000
Table 8-1: Global - Top Launched Vaccine Brand Sales (in Million US$), 2007 & 2012F
Table 8-2: Global - Forecast for Top Vaccine Brand Sales Under-development (in Million US$), 2012
Table 8-3: Global - Key Mergers & Acquisitions in Vaccine Market (2005 to 2008)
Table 8-4: Global - Major Vaccine Companies (Segmentation by Revenue)